Stereotactic Body Radiation Therapy Training Program 2024 (RP2501A-041024)

April 10, 2024 to April 12, 2024

The primary focus of this CME course is to help oncology programs in both large and small centers, academic and community practice, learn about the proper implementation of a viable and effective SBRT treatment practice. Covered topics will include the evolution of SBRT from roots in image-guided tumors in the body, guidelines for proper treatment, billing and compliance, physics and dosimetry of SBRT, clinical outcomes and treatment patterns in spine, liver, lung, GI and GU cancers, and description of various treatment platforms in clinical operation. This course, consisting of didactic lectures, interactive Q&A sessions, and simulation/treatment observation, is designed for radiation oncologists, medical physicists, medical dosimetrists, administrators and radiation therapists interested in implementing SBRT into clinical practice.

The planned cohort dates are April 10-12, 2024, August 28-30, 2024, October 16-18, 2024, and January 15-17, 2025.

Target Audience

This course is designed for radiation oncologists, medical physicists, medical dosimetrists, administrators and radiation therapists interested in implementing SBRT into clinical practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

1) Examine the rationale and basic biology for delivering ablative doses of radiation to demarcated tumors using SBRT and image-guided techniques;

2) Implement "on or off treatment" protocol based upon mature clinical data;

3) Identify treatment delivery options for initiating a clinical SBRT program at both large and small centers;

4) Demonstrate hands-on skills in the identification and delivery of SBRT treatments via simulated exercises; and

5.) Explain quality assurance and regulatory compliance requirements for implementing a clinical SBRT program.

Additional Information

AttachmentSize
File April 2024 SBRT Agenda-revised04.04.24.docx71.6 KB
Course summary
Available credit: 
  • 17.50 AMA
  • 17.50 Attendance
Course opens: 
04/10/2024
Course expires: 
01/17/2025
Event starts: 
04/10/2024 - 7:00am CDT
Event ends: 
04/12/2024 - 12:00pm CDT
Cost:
$0.00
Add to calendar: 
Rating: 
0
UT Southwestern Medical Center
Dallas, TX
United States
Committee member(s)

Kajal Desai, Department Administrator

has no relevant financial relationships to disclose at this time.

paul medin, PhD, DABR

has no relevant financial relationships to disclose at this time.

Robert Timmerman, MD

has a financial relationship (Grant Or Contract) with Varian Medical Systems;.
has a financial relationship (Grant Or Contract) with Accuray, Inc.;.
has a financial relationship (Grant Or Contract) with Elekta Oncology;.
Course Director(s)

paul medin, PhD, DABR

has no relevant financial relationships to disclose at this time.

Robert Timmerman, MD

has a financial relationship (Grant Or Contract) with Elekta Oncology;.
has a financial relationship (Grant Or Contract) with Varian Medical Systems;.
has a financial relationship (Grant Or Contract) with Accuray, Inc.;.

Zabi Wardak, MD

has no relevant financial relationships to disclose at this time.
Peer reviewer(s)

paul medin, PhD, DABR

has no relevant financial relationships to disclose at this time.

Robert Timmerman, MD

has a financial relationship (Grant Or Contract) with Accuray, Inc.;.
has a financial relationship (Grant Or Contract) with Elekta Oncology;.
has a financial relationship (Grant Or Contract) with Varian Medical Systems;.
Planner(s)

Kelsey Roach

has no relevant financial relationships to disclose at this time.

Zabi Wardak, MD

has no relevant financial relationships to disclose at this time.
Speaker(s)

Todd Aguilera, M.D. Ph.D.

has a financial relationship (Stock) with Avelas Biosciences;.
has a financial relationship (Intellectual Property Other) with Stanford University ;.
has a financial relationship (Intellectual Property Other) with UC San Diego;.
has a financial relationship (Grant Or Contract) with Apexigen Inc;.
has a financial relationship (Grant Or Contract) with Galera Therapeutics;.

Mona Arbab

has no relevant financial relationships to disclose at this time.

Thomas Banks, PhD, DABR

has no relevant financial relationships to disclose at this time.

Eric Chambers, MBA, BSRT (T), CPHQ

has no relevant financial relationships to disclose at this time.

Neil Desai, MD MHS

has a financial relationship (Grant Or Contract) with Boston Scientific;.

Jeffrey Dubas

has no relevant financial relationships to disclose at this time.

Raquibul Hannan, MD, PhD, Associate Professor

has no relevant financial relationships to disclose at this time.

Mu-han Lin

has no relevant financial relationships to disclose at this time.

paul medin, PhD, DABR

has no relevant financial relationships to disclose at this time.

David Parsons, PhD, DABR

has no relevant financial relationships to disclose at this time.

Arnold Pompos, Associate Professor of Physics

has no relevant financial relationships to disclose at this time.

David Sher, MD, MPH

has a financial relationship (Grant Or Contract) with Varian Medical Systems;.

Fan-Chi Su

has no relevant financial relationships to disclose at this time.

Robert Timmerman, MD

has a financial relationship (Grant Or Contract) with Accuray, Inc.;.
has a financial relationship (Grant Or Contract) with Elekta Oncology;.
has a financial relationship (Grant Or Contract) with Varian Medical Systems;.

Zabi Wardak, MD

has no relevant financial relationships to disclose at this time.

Kenneth Westover, MD, PhD, Associate Professor of Radiation Oncology and Biochemistry

has a financial relationship (Stock Options) with Vibliome Therapeutics;.
has a financial relationship (Professional Services) with Reactive biosciences;.

The University of Texas Southwestern Medical Center at Dallas is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas Southwestern Medical Center designates this live activity for a maximum of 17.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Available Credit

  • 17.50 AMA
  • 17.50 Attendance

Price

Cost:
$0.00
Please login or create an account to take this course.